Brit health care agency says no to earlier use of Zytiga

Britain's healthcare cost effectiveness agency NICE says J&J's (JNJ) Zytiga (abiraterone) is not worth giving to patients who have yet to receive chemotherapy. The drug is currently approved for use in some men after chemo.

Apparently, J&J's own economic model shows Zytiga is not cost effective when used earlier. The once-daily tablet costs 2,930 pounds ($4,900) for a 120-tablet regimen.

Institute of Cancer Research deputy chief executive Paul Workman is disappointed in NICE's decision and urges the parties to work together on a revised price that would make the economics attractive.

From other sites
Comments (1)
  • Electraglide
    , contributor
    Comments (2) | Send Message
    Wow! We had heard that Zytiga was not given to anyone until they had undergone chemo. Somehow, my husband slipped under the radar. It is now 14 years after a diagnosis of metastatic prostate cancer. Cancer was evident in his entire skeletal frame. His PSA was just under 500. He underwent all the standard treatments with various changes throughout the first 9 years. Then he had the good fortune to be accepted for Provenge. This drug does not work on the PSA count, and when he finished his PSA was up again to 465. However, he still felt very well. His doctor started him on Zytiga and the PSA dropped to .3 and has remained at that level for almost 3 years. The Provenge treatment gave his immune system such a boost, that he has not even had a cold in the last 5 years. However, it was the Zytiga that went after the cancer cells that were beginning to multiply.
    14 May 2014, 12:33 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs